Latest News and Press Releases

Amryt Supports Acromegaly Awareness Day 2022 DUBLIN, Ireland, and Boston MA, October 31, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...

The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25, 2022 Amryt (Nasdaq: AMYT), a global,...

Amryt Supports Global EB Awareness Week 2022 DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...

Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring,...

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly DUBLIN, Ireland, and Boston MA, October 18, 2022 Amryt (Nasdaq: AMYT), a global,...

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, October 17, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...

Amryt Supports FH Awareness Day – September 24, 2022 DUBLIN, Ireland, and Boston MA, September 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...

CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly Positive opinion based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, September 16, 2022, Amryt (Nasdaq:...

Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain UK MHRA approval follows on from recent European Commission approval of Filsuvez® DUBLIN,...